Diabetes, Obesity, and Cardiometabolic CARE
Comparative Effectiveness of Individual DPP-4 Inhibitors on Kidney Outcomes in Type 2 Diabetes With Moderate Cardiovascular Risk: A Target Trial Emulation
Cohort study of 115,091 peopleType 2 diabetes
Papers on alogliptin
14 papers2 new in 30 days
Tuesday, October 27
Monday, October 26
ESC Congress 2026 Abstract
Incremental cardiovascular benefit of GLP-1RA added to SGLT2i in type 2 diabetes: a target trial emulation in the US veterans health administration
Cohort study of 79,792 peopleType 2 diabetes
Friday, March 13
Journal of Medicinal Chemistry
Targeted Degradation of Dipeptidyl Peptidase-4 via Proteolysis-Targeting Chimera Technology for Sustained Glycemic Control in Type 2 Diabetes
Experiments in animalsType 2 diabetes
Friday, February 27
Naunyn-Schmiedeberg's Archives of Pharmacology
Musculoskeletal adverse events with incretin-based diabetes drugs: a FAERS pharmacovigilance study
Study of 15,052 peopleMusculoskeletal disease
Thursday, November 6
Journal of Personalized Medicine
Exploring the Evidence for Personalized Pharmacotherapy in Type 2 Diabetes-A Systematic Review
Systematic review of studies in peopleType 2 diabetes
Thursday, January 12
Journal of Basic and Clinical Physiology and Pharmacology
Anti-ageing effects of FDA-approved medicines: a focused review
ReviewInterventions
Tuesday, March 22
Diabetes, Obesity & Metabolism
Efficacy and safety of alogliptin versus acarbose in Chinese type 2 diabetes patients with high cardiovascular risk or coronary heart disease treated with aspirin and inadequately controlled with metformin monotherapy or drug-naive: A multicentre, randomized, open-label, prospective study (ACADEMIC)
Randomized trial in 1,088 peopleType 2 diabetes
Tuesday, January 15
Aging Cell
Alogliptin improves survival and health of mice on a high-fat diet
Experiments in miceInterventions
Wednesday, December 5
Endocrine Journal
Effect of additional administration of acarbose on blood glucose fluctuations and postprandial hyperglycemia in patients with type 2 diabetes mellitus under treatment with alogliptin
Non-randomized trial in 10 peopleHyperglycemia